Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications -------------------------------------------------------------- Partial Responses seen in liver, melanoma, gastro-esophageal junction, and head and neck cancers. -------------------------------------------------------------- Encouraging demonstration of the potential of SPEAR T-cell platform across multiple targets and a range of solid tumors ---------------------------------------------------------- two confirmed Partial Responses (PRs) – one in a patient with liver cancer and one in a patient with melanoma. ---------------------------------------------------------- There are also two unconfirmed PRs – one in a patient with gastro‑esophageal junction cancer and one in a patient with head and neck cancer ---------------------------------------------------------- These data further confirm the potential of Adaptimmune’s SPEAR T-cell platform for patients with multiple solid tumors. ---------------------------------------------------------- These responses demonstrate that our proprietary SPEAR T-cell platform is clearly active and can overcome the challenges of treating a range of solid tumors with a T-cell therapy product- ---------------------------------------------------------- These are early results and we need more patient data and durability information to determine which therapies to develop.